Cencora (NYSE:COR) Trading Up 1.9%

Cencora, Inc. (NYSE:COR - Get Free Report) shares traded up 1.9% on Tuesday . The company traded as high as $238.74 and last traded at $238.62. 175,382 shares changed hands during trading, a decline of 86% from the average session volume of 1,225,821 shares. The stock had previously closed at $234.21.

Analyst Ratings Changes

COR has been the subject of several research analyst reports. Leerink Partnrs reiterated an "outperform" rating on shares of Cencora in a research note on Monday, February 26th. SVB Leerink assumed coverage on shares of Cencora in a report on Monday, February 26th. They set an "outperform" rating and a $261.00 price objective for the company. Barclays began coverage on shares of Cencora in a research note on Wednesday, January 3rd. They issued an "overweight" rating and a $242.00 target price on the stock. StockNews.com upgraded Cencora from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Finally, Mizuho upped their price objective on Cencora from $192.00 to $224.00 and gave the company a "neutral" rating in a research note on Monday, February 5th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $218.22.

Cencora Trading Up 1.7 %

The firm has a market capitalization of $47.54 billion, a price-to-earnings ratio of 25.95, a price-to-earnings-growth ratio of 1.79 and a beta of 0.45. The company has a quick ratio of 0.52, a current ratio of 0.88 and a debt-to-equity ratio of 3.94. The firm's 50 day moving average is $237.44 and its 200 day moving average is $213.83.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, January 31st. The company reported $3.28 EPS for the quarter, beating the consensus estimate of $2.86 by $0.42. The business had revenue of $72.25 billion during the quarter, compared to the consensus estimate of $68.81 billion. Cencora had a return on equity of 323.23% and a net margin of 0.69%. During the same period in the prior year, the business posted $2.71 earnings per share. Equities analysts forecast that Cencora, Inc. will post 13.43 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 26th. Stockholders of record on Friday, February 9th were issued a $0.51 dividend. The ex-dividend date of this dividend was Thursday, February 8th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. This is a positive change from Cencora's previous quarterly dividend of $0.24. Cencora's dividend payout ratio is presently 22.22%.

Insider Buying and Selling

In related news, EVP Gina Clark sold 1,100 shares of the firm's stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $230.48, for a total transaction of $253,528.00. Following the completion of the sale, the executive vice president now directly owns 24,802 shares in the company, valued at $5,716,364.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,212,395 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $235.41, for a total value of $991,639,906.95. Following the completion of the sale, the insider now owns 26,277,561 shares of the company's stock, valued at approximately $6,186,000,635.01. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Gina Clark sold 1,100 shares of the firm's stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $230.48, for a total transaction of $253,528.00. Following the transaction, the executive vice president now directly owns 24,802 shares in the company, valued at approximately $5,716,364.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,220,472 shares of company stock valued at $993,554,798. Corporate insiders own 15.80% of the company's stock.

Institutional Trading of Cencora

Institutional investors and hedge funds have recently made changes to their positions in the stock. United Bank grew its stake in Cencora by 16.6% in the 1st quarter. United Bank now owns 3,632 shares of the company's stock valued at $562,000 after buying an additional 518 shares during the last quarter. Raymond James Trust N.A. grew its position in shares of Cencora by 29.9% in the first quarter. Raymond James Trust N.A. now owns 5,193 shares of the company's stock valued at $803,000 after purchasing an additional 1,194 shares during the last quarter. Synovus Financial Corp increased its stake in shares of Cencora by 123.4% in the first quarter. Synovus Financial Corp now owns 6,301 shares of the company's stock worth $975,000 after purchasing an additional 3,480 shares during the period. Vontobel Holding Ltd. increased its stake in shares of Cencora by 22.5% in the first quarter. Vontobel Holding Ltd. now owns 2,767 shares of the company's stock worth $430,000 after purchasing an additional 508 shares during the period. Finally, Blair William & Co. IL lifted its position in shares of Cencora by 12.4% during the 1st quarter. Blair William & Co. IL now owns 8,124 shares of the company's stock worth $1,257,000 after purchasing an additional 899 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.